FR10C0012I1 - - Google Patents

Info

Publication number
FR10C0012I1
FR10C0012I1 FR10C0012C FR10C0012I1 FR 10C0012 I1 FR10C0012 I1 FR 10C0012I1 FR 10C0012 C FR10C0012 C FR 10C0012C FR 10C0012 I1 FR10C0012 I1 FR 10C0012I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9449457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR10C0012(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR10C0012I1 publication Critical patent/FR10C0012I1/fr
Application granted granted Critical
Publication of FR10C0012I2 publication Critical patent/FR10C0012I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR10C0012C 1993-07-21 2010-03-04 Active FR10C0012I2 (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9308948A FR2707988B1 (fr) 1993-07-21 1993-07-21 Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
PCT/FR1994/000898 WO1995003312A1 (fr) 1993-07-21 1994-07-19 Derives antimitotiques des alcaloides binaires du catharanthus roseus

Publications (2)

Publication Number Publication Date
FR10C0012I1 true FR10C0012I1 (enExample) 2010-04-16
FR10C0012I2 FR10C0012I2 (enExample) 2011-04-01

Family

ID=9449457

Family Applications (2)

Application Number Title Priority Date Filing Date
FR9308948A Expired - Lifetime FR2707988B1 (fr) 1993-07-21 1993-07-21 Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR10C0012C Active FR10C0012I2 (enExample) 1993-07-21 2010-03-04

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR9308948A Expired - Lifetime FR2707988B1 (fr) 1993-07-21 1993-07-21 Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.

Country Status (15)

Country Link
US (1) US5620985A (enExample)
EP (1) EP0710240B1 (enExample)
JP (1) JP3606872B2 (enExample)
AT (1) ATE146477T1 (enExample)
AU (1) AU693460B2 (enExample)
BR (1) BR1100311A (enExample)
CA (1) CA2167694C (enExample)
DE (2) DE122010000012I1 (enExample)
DK (1) DK0710240T3 (enExample)
ES (1) ES2097659T3 (enExample)
FR (2) FR2707988B1 (enExample)
GR (1) GR3022659T3 (enExample)
LU (1) LU91660I2 (enExample)
NZ (2) NZ269172A (enExample)
WO (1) WO1995003312A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2737208A1 (fr) * 1995-07-28 1997-01-31 Pf Medicament Nouvelles fluorovindolines, precurseurs d'analogues de la vinblastine et de la vinorelbine,leurs procedes de preparation et leur utilisation comme medicament
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
FR2783522A1 (fr) * 1998-09-21 2000-03-24 Pf Medicament Composes derives d'alcaloides de vinca, leur preparation et leur application en therapeutique
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US6890558B2 (en) * 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7238704B2 (en) 2003-12-04 2007-07-03 Amr Technology, Inc. Vinca derivatives
EP1694330A4 (en) 2003-12-04 2009-06-24 Amr Technology Inc DERIVATIVES OF VINORELBINE
US20110015221A1 (en) * 2003-12-23 2011-01-20 Pierre Fabre Medicament Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
WO2005087808A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Growth factor binding constructs materials and methods
FR2894966B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Nouvelle forme cristalline de la vinflunine
CN101421282B (zh) 2006-02-17 2013-08-14 俄勒冈州由俄勒冈州立大学代表高等教育委员会行使 用长春花生物碱n-氧化物和类似物治疗过度增殖性疾病
CN101108859A (zh) * 2006-07-17 2008-01-23 上海恒瑞医药有限公司 长春碱类化合物、其制备方法及其在医药上的用途
WO2008033935A2 (en) * 2006-09-12 2008-03-20 Amr Technology, Inc. Vinorelbine derivatives
US8039453B2 (en) * 2006-09-12 2011-10-18 Albany Molecular Research, Inc. Vinca derivatives
FR2905949B1 (fr) 2006-09-20 2008-11-21 Pierre Fabre Medicament Sa Derives fluores de catharanthine, leur preparation et leur utilisation comme precurseurs d'alcaloides dimeres de vinca
CN101235046B (zh) * 2007-01-29 2010-09-08 中国科学院上海药物研究所 长春碱衍生物、其制备方法和用途、以及包含该衍生物的药物组合物
FR2912406B1 (fr) 2007-02-13 2009-05-08 Pierre Fabre Medicament Sa Sels cristalins anhydres de vinflunine, procede de preparation et utilisation en tant que medicament et moyen de purification de la vinflunine.
EP1997534A1 (en) * 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
US20090076055A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched vinflunine
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CL2009002208A1 (es) 2008-12-23 2010-10-29 Gilead Pharmasset Llc Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
CN103788117A (zh) * 2012-10-30 2014-05-14 何小解 一种脱水长春碱、长春瑞滨及长春氟宁连续化合成工艺
HU230462B1 (hu) 2013-05-30 2016-07-28 Richter Gedeon Nyrt. Új bisz-indol alkaloidok mint rákellenes gyógyszerek
AU2015205995A1 (en) 2014-01-15 2016-07-28 Centre National De La Recherche Scientifique (Cnrs) Water soluble 4-azapodophyllotoxin analogs
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
JP6912386B2 (ja) 2015-01-26 2021-08-04 ザ ユニバーシティー オブ シカゴ 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞
RU2730521C2 (ru) * 2016-03-09 2020-08-24 Синбиас Фарма АГ Винорелбина монотартрат и его фармацевтическое применение
EP3481422A1 (en) 2016-07-06 2019-05-15 Pierre Fabre Medicament Vinflunine and pd1 and/or pdl1 inhibitor as pharmaceutical combination
CA3071599A1 (en) 2017-08-07 2019-02-14 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
JP7682797B2 (ja) 2019-03-20 2025-05-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クローディン６二重特異性抗体
ES3017207T3 (en) 2019-03-20 2025-05-12 Univ California Claudin-6 antibodies and drug conjugates
US20220195059A1 (en) 2019-04-30 2022-06-23 Instituto de Medicina Molecular João Lobo Antunes Rank Pathway Inhibitors in Combination with CDK Inhibitors
WO2020263793A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
FR3140369B1 (fr) 2022-10-04 2025-07-25 Univ Poitiers Procédé de fluoration et/ou cyclisation d’un alcène ou alcyne aminé en flux continu et installation pour la mise en œuvre du procédé

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2296418B1 (enExample) * 1974-12-30 1978-07-21 Anvar
US4110330A (en) * 1977-05-27 1978-08-29 Eli Lilly And Company 5'-Acetonylvincristine and related compounds
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4307100A (en) * 1978-08-24 1981-12-22 Agence Nationale De Valorisation De La Recherche (Anvar) Nor bis-indole compounds usable as medicaments
US4320058A (en) * 1980-12-29 1982-03-16 Eli Lilly And Company 20'-Hydroxyvinblastine and related compounds
HU193772B (en) * 1985-06-12 1987-11-30 Richter Gedeon Vegyeszet Process for producing new nitro-bis-indole derivatives

Also Published As

Publication number Publication date
WO1995003312A1 (fr) 1995-02-02
JP3606872B2 (ja) 2005-01-05
ES2097659T3 (es) 1997-04-01
FR2707988A1 (fr) 1995-01-27
CA2167694A1 (fr) 1995-02-02
BR1100311A (pt) 1999-08-31
JPH09500634A (ja) 1997-01-21
DK0710240T3 (da) 1997-06-02
DE69401216D1 (de) 1997-01-30
FR10C0012I2 (enExample) 2011-04-01
AU693460B2 (en) 1998-07-02
DE122010000012I1 (de) 2010-07-08
DE69401216T2 (de) 1997-07-03
US5620985A (en) 1997-04-15
LU91660I2 (fr) 2010-05-10
ATE146477T1 (de) 1997-01-15
NZ269172A (en) 1997-10-24
FR2707988B1 (fr) 1995-10-13
GR3022659T3 (en) 1997-05-31
EP0710240B1 (fr) 1996-12-18
CA2167694C (fr) 2007-03-06
AU7266694A (en) 1995-02-20
NZ328612A (en) 2000-05-26
EP0710240A1 (fr) 1996-05-08

Similar Documents

Publication Publication Date Title
FR10C0012I2 (enExample)
EP0708807A4 (enExample)
EP0663347A3 (enExample)
DK21393D0 (enExample)
FR2714307B1 (enExample)
IN178878B (enExample)
ECSDI930134S (enExample)
IN182424B (enExample)
IN180773B (enExample)
IN179435B (enExample)
IN178963B (enExample)
IN186022B (enExample)
IN186840B (enExample)
ECSDI930120S (enExample)
IN182747B (enExample)
ECSDI930138S (enExample)
DK22193A (enExample)
ECSDI930162S (enExample)
DK5993A (enExample)
ECSDI930151S (enExample)
ECSDI930153S (enExample)
BR9300176A (enExample)
ECSDI930174S (enExample)
ECSMU930018U (enExample)
ECSMU930023U (enExample)